New Drugs and Clinical Research · us
At-Home Injection Option Arrives for Thyroid Eye Disease: Enspryng Wins FDA Approval
Subcutaneous maintenance injections every four weeks allow some treatment to move home. However, statistical results from the two pivotal trials differed, making the magnitude of efficacy and continued monitoring as important as convenience.
Bulging eyes and double vision already make daily life difficult for people with thyroid eye disease, and traveling to treatment facilities adds another burden. The U.S. Food and Drug Administration (FDA) has approved Enspryng for adults with thyroid eye disease, adding an option for subcutaneous injection at home. Roche’s Genentech announced the news on October 15, 2026, and Roche issued a global announcement the following day. According to the company, patients or caregivers can administer the drug after training by a healthcare professional, with injections every four weeks during maintenance treatment.
Thyroid eye disease is an autoimmune disease affecting the eyes and surrounding tissues. It can cause swelling, pain, bulging eyes and double vision, and can threaten sight in severe cases. Enspryng’s active ingredient, satralizumab, known in the United States as satralizumab-mwge, is a monoclonal antibody that blocks the interleukin-6 receptor (IL-6R), thereby inhibiting inflammatory signaling. This approval makes it the first IL-6R inhibitor for this disease in the United States and the first subcutaneous therapy that can be used at home. Genentech said the adult indication is unrestricted by disease severity or duration.
Supporting the approval were SatraGO-1 and SatraGO-2, two identically designed Phase III randomized, placebo-controlled trials that enrolled a total of 258 people across 19 countries, including patients with active moderate-to-severe and chronic thyroid eye disease. The primary efficacy measure focused on patients with active moderate-to-severe disease: the proportion whose study eye showed a reduction in proptosis of at least 2 millimeters from baseline at week 24 of treatment. This criterion measures improvement in bulging eyes and cannot be directly equated with restoration of vision.
Both studies did not meet their targets. SatraGO-1 did not meet its prespecified primary efficacy endpoint at week 24. In SatraGO-2, among patients with active disease, the proptosis response rate was 52.9% in the Enspryng group and 23.4% in the placebo group; the proportions with improvement in double vision were 60.7% and 25.8%, respectively. Roche said an overall analysis of SatraGO-2 that included patients with active and chronic disease also showed results in a consistent direction, but this does not mean that the magnitude of benefit was the same across patient groups.
Addressing why the two trials reached different statistical conclusions, César Briceño, an ophthalmologist involved in the research, told Ophthalmology Times that treatment effects were fairly consistent and that the difference may primarily have stemmed from placebo response rates. This is an investigator’s interpretation and does not erase the fact that one trial failed to meet its primary endpoint. He also noted that the magnitude of improvement in proptosis was less pronounced than results reported in current studies of IGF-1R antagonists, but remained clinically meaningful. Comparisons across different trials, however, are insufficient to establish the superiority of one drug over another.
At-home administration also requires comprehensive safety monitoring. No new safety signals were identified in the two SatraGO trials, but the prescribing information released by Genentech still lists a risk of serious infections, requires screening for hepatitis and tuberculosis before treatment, and calls for monitoring liver enzymes and neutrophil counts during treatment. “No new signals” means that no new issues beyond the known risks were identified; it does not mean there are no side effects.
For patients with limited transportation, those living far from infusion centers, or those who find commuting difficult because of double vision, the change in administration has practical significance. However, while injections can be given at home, infection assessments, blood tests and eye follow-up still need to be arranged. This approval expands treatment options. How efficacy, physical condition and the burden of accessing care are balanced will determine how much this convenience helps different patients.